No Evidence of Benefit of Lithium on Survival in Patients with ALS

Lithium in patients with amyotrophic lateral sclerosis (LiCALS): a phase 3 multicentre, randomised, double-blind, placebo-controlled trial
From the UKMND-LiCALS Study Group
Summary article posted online in The Lancet Neurology, February 27, 2013 •

Background

Lithium has neuroprotective effects in cell and animal models of amyotrophic lateral sclerosis (ALS), and a small pilot study in patients with ALS showed a [...]

ALS Community Tells FDA ‘We Have No Time To Waste’; Urges Changes in Trial Design and Review Process

Because of the relentless effects of ALS, a diverse group of ALS voices — patients, families, organizations and the community — came together to speak about their experiences with ALS and to urge the FDA to work with them to overcome some of the obstacles faced in ALS research, clinical trials and standards of care.